BioTech Breakthrough, a leading independent market intelligence organization evaluating top-tier innovations in the global life sciences and biotechnology sector, has announced the winners of its fifth annual BioTech Breakthrough Awards—with Evergreen Therapeutics receiving the Drug Development Innovation Award for the transformative role of its proprietary AI platform in accelerating pipeline development.

Evergreen Therapeutics has announced positive Phase II clinical data for EG-501, an investigational, AI-enabled therapy for cognitive impairment in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). As a potential first-in-disease therapy, these results underscore the significant promise of integrating AI with drug R&D to address complex conditions.

Evergreen Therapeutics announced that its AI‑enabled small molecule drug candidate EG‑101, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase I clinical trial.

Evergreen Therapeutics has announced that patient enrollment has been completed for the Phase II clinical trial of EG‑501, its AI‑enabled drug candidate for cognitive impairment associated with neuropsychiatric systemic lupus erythematosus (NPSLE). The trial is being conducted in the United States.

Evergreen Therapeutics recently announced that its AI‑enabled candidate EG‑501 has reached a major milestone. The ongoing Phase II trial has completed enrollment of half its target participants, and an interim analysis of the data has returned positive outcomes.

On June 5, 2023, BOJIMED and Evergreen signed a strategic cooperation agreement. Focusing on clinical trials, they will leverage AI to address R&D bottlenecks, boosting innovative drug development efficiency and commercialization.